Skip to main content

Table 3 Correlation between clinical data and DTCs, CTCs, and slCTCs before therapy

From: Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

  Total DTC-positive, n (%) p Value Total CTC-positive, n (%) p Value Total slCTC-positive (%) p Value
Tumor size 139 37 (27)   132 31 (23)   89 44 (49)  
 cT1 32 5 (16) 0.27 32 10 (31) 0.26 26 15 (58) 0.56
 cT2 86 25 (29)   81 19 (23)   53 25 (47)  
 Above cT2 21 7 (33)   19 2 (11)   10 4 (40)  
Nodal status 141 38 (27)   134 32 (24)   90 45 (50)  
 cN0 77 28 (36) 0.03 74 21 (28) 0.62 46 24 (52) 0.44
 cN1 56 9 (16)   53 11 (21)   39 20 (51)  
 cN2, cN3 8 1 (13)   7 0 (0)   5 1 (20)  
Histology 140 37 (26)   133 32 (24)   90 45 (50)  
 Ductal 106 27 (25) 0.046 99 22 (22) 0.70 67 33 (49) 0.80
 Lobular 16 8 (50)   17 5 (29)   12 7 (58)  
 Others 18 2 (11)   17 5 (29)   11 5 (45)  
Grade 139 38 (27)   132 32 (24)   89 44 (49)  
 I 9 2 (22) 0.87 12 0 (0) 0.31 5 3 (60)  
 II 65 19 (29)   59 12 (20)   40 17 (43) 0.49
 III 65 17 (26)   61 20 (33)   44 24 (55)  
ER status 141 38 (27)   134 32 (24)   90 45 (50)  
 Negative 43 8 (17) 0.14 41 8 (20) 0.43 24 11 (46) 0.63
 Positive 98 30 (31)   93 24 (26)   66 34 (52)  
PR status 141 38 (27)   134 32 (24)   90 45 (50)  
 Negative 60 14 (23) 0.41 56 13 (23) 0.88 39 19 (49) 0.83
 Positive 81 24 (30)   78 19 (24)   51 26 (51)  
  1. CTC circulating tumor cell, DTC disseminated tumor cell, ER estrogen receptor, PR progesterone receptor, slCTC stem cell–like circulating tumor cell